Collaboration will access data from the ECLS trial, the large randomized study into the utility of EarlyCDT Lung in asymptomatic screening.
Oncimmune Holdings plc (AIM: ONC.L), the leading global immunodiagnostics group, announces a collaboration with Siemens Healthineers aimed at improving malignancy risk assessment of Indeterminate Pulmonary Nodules (“IPNs”).
Lung cancer has the highest mortality rate and one of the worst five-year survival rates of all cancers1. What makes lung cancer so deadly is that the symptoms are non-specific and patients often only seek medical attention when tumors have exceeded a critical size, or when cancer cells have attacked the lymph nodes or have metastasized. The best chance of survival is to diagnose lung cancer as early as possible. Early detection and the introduction of screening programs have the potential to substantially improve lung cancer healthcare and clinical outcomes.
The collaboration brings together Oncimmune’s EarlyCDT Lung blood test with Siemens Healthineers’ AI-Rad Companion Chest CT (computerised tomography), an AI-powered radiology assistant that supports radiologists by performing automatic post-processing, quantifying and interpreting data. By combining autoantibody biomarker data with imaging results, it is anticipated that malignancy risk assessment of IPNs can be improved. The collaboration will access data from the Early Detection of Cancer of the Lung Scotland (ECLS) trial, the large randomised study into the utility of EarlyCDT Lung in asymptomatic screening.
Dr Adam M Hill, CEO of Oncimmune said: “If lung cancer is detected early when it doesn’t yet cause symptoms, the chances for curative treatment to work are good: the average five-year survival rate for the earliest stage of the disease can be as high as 90%. Oncimmune’s easy-to-use EarlyCDT Lung blood test has proven utility in successfully triaging patients with cancerous nodules into early intervention. It is our hope that combining this test with Siemens Healthineers’ AI-Rad Companion Chest CT will improve diagnostic accuracy in those patients with more difficult to diagnose lung cancer.”
Sebastian Schmidt, MD, Head of Medical Affairs, Innovation and Strategy at Siemens Healthineers Computed Tomography said: “Lung cancer screening is proven to work and reduce mortality of this devastating disease. We believe that additionally, further improvement in outcomes and efficiency gains will be possible by combining imaging with lab markers – our collaboration with Oncimmune is an important first step in this direction.”
For further information:
Oncimmune Holdings plc
Dr Adam M Hill, Chief Executive Officer
Matthew Hall, Chief Financial Officer
contact@oncimmune.co.uk
Singer Capital Markets (Nominated Adviser and Broker)
Aubrey Powell, Harry Gooden, George Tzimas, James Fischer
+44 (0)20 7496 3000